Abstract:Objective To investigate the preventive effects of rosiglitazone on nonalcoholic steatohepatitis (NASH) rats and to explore the potential mechanisms in modulating peroxisome proliferator-activated receptor gamma (PPARγ),nuclear factor kappa B (NF-κB),and cyclooxygenase-2 (COX-2) expression.Methods Thirty male SD rats were assigned into the normal group ( n =10),the model group ( n =10),rosiglitazone prevention group [ n =10,simultaneously 4mg/( kg · d) gavage daily at beginning].Liver appearance,liver index,and histological changes were assessed.Serum tumor necrosis factor-o (TNF-c) and prostaglandin E2 (PGE2) were determined using enzyme-linked immunosorbent assay.The expressions of PPARγ,NF-κB,and COX-2 in liver were determined using immunohistochemical methods.The mRNA and protein expressions of COX-2 were disclosed by real-time polymerase chain reaction and Western blot analysis.Results Compared with the normal group,the liver index significantly increased in model group (3.92 ±0.72 vs.5.71 ± 1.05,P =0.004).HE and Masson staining showed significantly increased steatosis,inflammation,and fibrosis.The serum levels of TNF-α,PGE2 in high-fat-diet-fed rats were significantly increased ( 11.72 ± 2.47 vs.29.39 ± 5.32,P =0.002 ; 236.60 ± 24.90vs.288.24 ± 17.17,P =0.004).Immunohistochemistry showed NF-κB and COX-2 in livers were significantly elevated,but PPARγ wasdecreased in nonalcoholic steatohepatitis rats.Real-time polymerase chain reaction and Western blot found mRNA and protein expressions of COX-2 were increased in the model group (0.57 ± 0.08 vs.2.83 ± 0.24,P =0.0007 ; 0.38 ± 0.03 vs.1.00 ± 0.03,P =0.004).Compared with the model group,the expressions of PPARγsignificantly increased and the expressions of NF-κB and COX-2 significantly decreased ( mRNA:2.83 ± 0.24 vs.0.46 ± 0.11,P =0.002 ; protein: 1.00 ± 0.03 vs.0.62 ± 0.02,P =0.006 ) in the rosiglitazone prevention group.Conclusion By inhibiting NF-κB and COX-2 expressions,rosiglitazone can reduce insulin resistance and then prevent the occurrence and deve lopment of nonalcoholic steatohepatitis.

Reduction of Serum Advanced Glycosylation End Products-Peptides and Monocyte Chemoattractant Protein-1 by Rosiglitazone in Type 2 Diabetic Rats

Reduction of serum advanced glycosylation end products-peptides and monocyte chemoattractant protein-1 by rosiglitazone in type 2 diabetic rats

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

Effect of Pioglitazone on Serum Advanced Glycosylation End Product Peptide and Monocyte Chemoattractant Protein-1 in Type 2 Diabetic Patients

The Effect of Rosiglitazone on the Blood Serum Monocyte Chemoattractant Protein-1 Levels of Diabetic Rats

Efficacy and safety of rosiglitazone hydrochloride in the treatment of patients with type 2 diabetes mellitus

Effects of improved insulin resistance on the level of serum glucagon-like peptide-1 in type 2 diabetic patients

Effect of rosiglitazone on the expression of fractalkine in renal cortex of type 2 diabetic rats

Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression

Inhibitory Effects of Rosiglitazone on the Synthesis of Reactive Oxygen Species and the Expression of Monocyte Ehemoattractant Protein 1 in Rat Mesangial Cells Cultured in High Glucose

Rosiglitazone maleate inhibits the hyperexpression of RANTES induced by advanced glycosylation end products in human renal mesangial cells (HRMC)

Rosiglitazone Ameliorates Diabetic Nephropathy by Inhibiting Reactive Oxygen Species and Its Downstream-Signaling Pathways

Rosiglitazone alleviates vascular endothelial dysfunction in type 2 diabetic rats

Effect of rosiglitazone on the myocardial interstitial fibrosis and cytokines expression of diabetic rats

Protective Effects of Rosiglitazone on Non-Alcoholic Steatohepatitis in Rats

Effects of Rosiglitazone on vascular structure and expression of phospholipase A2 in rats with type 1 diabetes mellitus

Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease

Relationship Between Protective Effects of Rosiglitazone on Endothelium and Endogenous Nitric Oxide Synthase Inhibitor in Streptozotocin-Induced Diabetic Rats and Cultured Endothelial Cells

The effect of rosiglitazone on the serum intercellular adhesion molecule-1 ( ICAM-1 ) levels of diabetic rats